Fangzhou (HKSE:06086) Research & Development: HK$0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06086 Fangzhou Inc HKSE:06086
11 GF Score
Price HK$0.73
! 3 Warning Signs
View Full Analysis

What is Fangzhou Research & Development?

Fangzhou HKSE:06086 -2.67% 11 Research & Development is HK$0 Mil as of Dec. 2025. GuruFocus rates HKSE:06086 with a GF Score™ of 11/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Fangzhou's Research & Development for the six months ended in Dec. 2025 was HK$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0 Mil.

Fangzhou  (HKSE:06086) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Fangzhou Research & Development Related Terms

Fangzhou Research & Development Historical Data

* Premium members only.

The historical data trend for Fangzhou's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fangzhou Research & Development Chart

Fangzhou Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
56.26 68.99 45.43 0.00 0.00

Fangzhou Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:06086
11GF Score
Fangzhou Inc HKSE:06086
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fangzhou Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$0 Mil mean?
Fangzhou (HKSE:06086) has a Research & Development of HK$0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Fangzhou and its competitors.
Is Fangzhou's Research & Development too high?
Fangzhou's current Research & Development is HK$0 Mil. Overall, Fangzhou has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Fangzhou's Research & Development compare to competitors?
Fangzhou's Research & Development of HK$0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Fangzhou and its competitors. Fangzhou's current Research & Development is HK$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fangzhou stock overvalued right now?
Fangzhou (HKSE:06086) has a current Research & Development of HK$0 Mil. The current Research & Development is HK$0 Mil. Fangzhou's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Fangzhou (HKSE:06086), the current Research & Development is HK$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fangzhou Business Description

Address 4th Street, Floor 1-2, Building S, Kehui Jingu, No. 99, Science Avenue, Luogang Science City, Huangpu District, Guangdong Province, Guangzhou, CHN
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services, Wholesale and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
11GF Score

Get the complete analysis for HKSE:06086

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.73
Price